Close Menu

NEW YORK – UK immunodiagnostics company Oncimmune announced on Thursday an exclusive commercial partnership with R-Pharm for the use of Oncimmune's EarlyCDT Lung test in Russia and member states of the Eurasian Customs Union.

The ECU comprises the Republic of Belarus, Kazakhstan, Armenia, and Kyrgyzstan. Additionally, under the terms of the agreement, R-Pharm has the option to extend the use of EarlyCDT Lung into Azerbaijan, Turkmenistan, Tajikistan, Ukraine, Uzbekistan, and Georgia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.